PURCHASING ACTEMRA^® (tocilizumab)

For questions about current availability for Actemra IV or SC please contact the Patient Resource Center at (877) 436-3683.

Thank you for your continued patience, Genentech is pleased to announce stable supply of all ACTEMRA® (tocilizumab) configurations SC and IV to support uninterrupted access for patients.

Due to increased manufacturing capacity, allocations to all configurations SC (Pre-filled Syringe and ACTPen®) and IV (80mg, 200mg and 400mg) have been removed in order to reestablish normal ordering.
Each distributor may have a different approach to managing their inventory to their respective customers.
Please note that the most up-to-date information on product availability across the Actemra IV and/or SC formulations will be available through your authorized distributors. For Actemra IV and/or SC availability information, customers may refer to the distributors’ online ordering portal or customer service line.

Update to Return Goods Policy for Actemra IV:

Genentech will not accept returns for Actemra IV purchased on or after August 30, 2021 until further notice. The updated policy for expired returns is now available.

Protecting your patients from illegitimate medicines

ACTEMRA is available only through authorized distributors that have made a commitment to product integrity.

Be cautious of new or unfamiliar distributors that offer ACTEMRA at substantially lower prices that may be "too good to be true"; the product being offered may be illegitimate.

If you suspect that you have received an illegitimate medicine, contact Genentech's Product Complaint Hotline at 1-800-334-0290, and file a report with the FDA’s Office of Criminal Investigations (OCI): call 1-800-551-3989 or visit www.accessdata.fda.gov/scripts/email/oc/oci/contact.cfm

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

PURCHASING ACTEMRA® (tocilizumab)

PURCHASING ACTEMRA^® (tocilizumab)